Should diffuse bronchiectasis still be considered a CFTR-related disorder?

Journal of Cystic Fibrosis

Volumn 14, Issue 5, 2015, Pages 646-653

  Bergougnoux, Anne ^a,b   Viart, Victoria ^a,b   Miro, Julie ^b,c   Bommart, Sébastien ^a,c,d   Molinari, Nicolas ^a,c,d   des Georges, Marie ^b   Claustres, Mireille ^b,c   Chiron, Raphaël ^a   Taulan Cadars, Magali ^b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY OF MONTPELLIER   (France)

Author keywords

CFTR gene; Diffuse bronchiectasis; Functional analysis; Variants classification

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN; DNA;

ADULT; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DIFFUSE BRONCHIECTASIS; DNA FLANKING REGION; GENE FREQUENCY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; SWEAT TEST; CELL LINE; DNA MUTATIONAL ANALYSIS; FEMALE; FRANCE; GENETICS; INCIDENCE; LUNG; MALE; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; BRONCHIECTASIS; CELL LINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FRANCE; HUMANS; INCIDENCE; LUNG; MALE; MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84940955521     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.02.012     Document Type: Article

References (35)

1. Dumur V., Lafitte J.J., Gervais R., Debaecker D., Kesteloot M., Lalau G., et al. Abnormal distribution of cystic fibrosis delta F508 allele in adults with chronic bronchial hypersecretion. Lancet 2 juin 1990, 335(8701):1340.
2. Poller W., Faber J.P., Scholz S., Olek K., Müller K.M. Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease. Application in the identification of a cystic fibrosis patient with atypical clinical course. Klin Wochenschr 16 sept 1991, 69(14):657-663.
3. Gervais R., Lafitte J.J., Dumur V., Kesteloot M., Lalau G., Houdret N., et al. Sweat chloride and delta F508 mutation in chronic bronchitis or bronchiectasis. Lancet 16 oct 1993, 342(8877):997.
4. Bienvenu T., Sermet-Gaudelus I., Burgel P.-R., Hubert D., Crestani B., Bassinet L., et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010, 181(10):1078-1084.
5. Bombieri C., Benetazzo M., Saccomani A., Belpinati F., Gilè L.S., Luisetti M., et al. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet déc 1998, 103(6):718-722.
6. Girodon E., Cazeneuve C., Lebargy F., Chinet T., Costes B., Ghanem N., et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet juin 1997, 5(3):149-155.
7. Tzetis M., Efthymiadou A., Strofalis S., Psychou P., Dimakou A., Pouliou E., et al. CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet mars 2001, 108(3):216-221.
8. Casals T., De-Gracia J., Gallego M., Dorca J., Rodríguez-Sanchón B., Ramos M.D., et al. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?. Clin Genet juin 2004, 65(6):490-495. 10.1111/j.0009-9163.2004.00265.x.
9. Bareil C., Guittard C., Altieri J.-P., Templin C., Claustres M., des Georges M. Comprehensive and rapid genotyping of mutations and haplotypes in congenital bilateral absence of the vas deferens and other cystic fibrosis transmembrane conductance regulator-related disorders. J Mol Diagn nov 2007, 9(5):582-588. 10.2353/jmoldx.2007.070040.
10. Estivill X., Bancells C., Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF mutation analysis consortium. Hum Mutat 1997, 10(2):135-154. 10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.0.CO;2-J.
11. Scotet V., Barton D.E., Watson J.B.G., Audrézet M.-P., McDevitt T., McQuaid S., et al. Comparison of the CFTR mutation spectrum in three cohorts of patients of Celtic origin from Brittany (France) and Ireland. Hum Mutat juill 2003, 22(1):105. 10.1002/humu.9158.
12. Desmet F.-O., Hamroun D., Lalande M., Collod-Béroud G., Claustres M., Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res mai 2009, 37(9):e67. 10.1093/nar/gkp215.
13. Viart V., Des Georges M., Claustres M., Taulan M. Functional analysis of a promoter variant identified in the CFTR gene in cis of a frameshift mutation. Eur J Hum Genet févr 2012, 20(2):180-184. 10.1038/ejhg.2011.161.
14. Viart V., Bergougnoux A., Bonini J., Varilh J., Chiron R., Tabary O., et al. Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis. Eur Respir J 3 sept 2014, 10.1183/09031936.00113214.
15. Lopez E., Viart V., Guittard C., Templin C., René C., Méchin D., et al. Variants in CFTR untranslated regions are associated with congenital bilateral absence of the vas deferens. J Med Genet mars 2011, 48(3):152-159. 10.1136/jmg.2010.081851.
16. Bareil C., Thèze C., Béroud C., Hamroun D., Guittard C., René C., et al. UMD-CFTR: a database dedicated to CF and CFTR-related disorders. Hum Mutat sept 2010, 31(9):1011-1019. 10.1002/humu.21316.
17. El-Seedy A., Girodon E., Norez C., Pajaud J., Pasquet M.-C., de Becdelièvre A., et al. CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. Hum Mutat nov 2012, 33(11):1557-1565. 10.1002/humu.22129.
18. René C., Paulet D., Girodon E., Costa C., Lalau G., Leclerc J., et al. p.Ser1235Arg should no longer be considered as a cystic fibrosis mutation: results from a large collaborative study. Eur J Hum Genet janv 2011, 19(1):36-42. 10.1038/ejhg.2010.137.
19. Pagani F., Stuani C., Tzetis M., Kanavakis E., Efthymiadou A., Doudounakis S., et al. New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet 15 mai 2003, 12(10):1111-1120.
20. Aznarez I., Chan E.M., Zielenski J., Blencowe B.J., Tsui L.-C. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet 15 aoÛt 2003, 12(16):2031-2040.
21. Ward C.L., Kopito R.R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 14 oct 1994, 269(41):25710-25718.
22. Sosnay P.R., Siklosi K.R., Van Goor F., Kaniecki K., Yu H., Sharma N., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet oct 2013, 45(10):1160-1167. 10.1038/ng.2745.
23. Milosevic K., Nikolic A., Divac Rankov A., Ljujic M., Nestorovic B., Radojkovic D. Analysis of CFTR gene variants in idiopathic bronchiectasis in Serbian children. Pediatr Allergy Immunol Pulmonol juin 2013, 26(2):93-98. 10.1089/ped.2013.0238.
24. Beekman J.M., Sermet-Gaudelus I., de Boeck K., Gonska T., Derichs N., Mall M.A., et al. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. J Cyst Fibros juill 2014, 13(4):363-372. 10.1016/j.jcf.2014.05.007.
25. Dannhoffer L., Blouquit-Laye S., Regnier A., Chinet T. Functional properties of mixed cystic fibrosis and normal bronchial epithelial cell cultures. Am J Respir Cell Mol Biol juin 2009, 40(6):717-723. 10.1165/rcmb.2008-0018OC.
26. Accurso F.J., Van Goor F., Zha J., Stone A.J., Dong Q., Ordonez C.L., et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros mars 2014, 13(2):139-147.
27. Raju S.V., Jackson P.L., Courville C.A., McNicholas C.M., Sloane P.A., Sabbatini G., et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 1 déc 2013, 188(11):1321-1330. 10.1164/rccm.201304-0733OC.
28. Cantin A.M., Hanrahan J.W., Bilodeau G., Ellis L., Dupuis A., Liao J., et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 15 mai 2006, 173(10):1139-1144. 10.1164/rccm.200508-1330OC.
29. Clunes L.A., Davies C.M., Coakley R.D., Aleksandrov A.A., Henderson A.G., Zeman K.L., et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J févr 2012, 26(2):533-545. 10.1096/fj.11-192377.
30. Bakouh N., Bienvenu T., Thomas A., Ehrenfeld J., Liote H., Roussel D., et al. Characterization of SLC26A9 in patients with CF-like lung disease. Hum Mutat oct 2013, 34(10):1404-1414. 10.1002/humu.22382.
31. Cho M.H., Boutaoui N., Klanderman B.J., Sylvia J.S., Ziniti J.P., Hersh C.P., et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet mars 2010, 42(3):200-202. 10.1038/ng.535.
32. Moffatt M.F., Gut I.G., Demenais F., Strachan D.P., Bouzigon E., Heath S., et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 23 sept 2010, 363(13):1211-1221. 10.1056/NEJMoa0906312.
33. http://www.ncbi.nlm.nih.gov.gate2.inist.fr/SNP/.
34. http://www.hgvs.org/mutnomen/.
35. http://www.genet.sickkids.on.ca/app.